Sanofi reported that AlphaMedix, its lead targeted alpha therapy developed with Orano Med and RadioMedix, met the primary endpoints in a Phase 2 study of unresectable or metastatic gastroenteropancreatic neuroendocrine tumors (GEP‑NETs). In a 61‑patient study split by prior Lutathera exposure, AlphaMedix achieved the study’s overall response rate and demonstrated a manageable safety profile. Sanofi paid roughly €100 million upfront to acquire the asset and has touted the readout as validating the 212Pb radiopharmaceutical platform. Company executives said secondary endpoints showed benefits in progression‑free and overall survival and signaled plans to use the data in discussions with regulators and at upcoming medical meetings. The result reinforces industry momentum behind targeted alpha emitters as precision oncology tools and could accelerate regulatory conversations and broader development across tumor types if subsequent cohorts replicate activity.